Reevoo to Bring Authentic Customer Reviews to the Travel Sector at ITB Berlin
‘Verified traveller’ model protects reputations by preventing fake reviews
Consumer-written travel reviews have never been more important to the booking process, but too many companies are missing out on their full potential, says social commerce company Reevoo. The company will demonstrate the value of customer reviews and social commerce solutions to the travel sector at ITB Berlin (7-11 March, Messe Berlin).
Reevoo founder and chief executive Richard Anson said: “Ratings and reviews are now essential tools for business which can drive extra web traffic and increase sales: Reevoo’s solutions have been proven to increase sales by an average of 18%. But, in relying on external review sites or DIY solutions, many travel companies may be losing some of the benefits. Worse, they risk tarnishing their reputation with the ongoing controversy over fake traveller reviews.
“Trust is clearly critical for travel customers. 88% of travellers consult reviews before making bookings, yet a recent Reevoo survey revealed that 70% have some concern about reviews not being trustworthy. This is a cause of concern for all stakeholders, and emphasises the need for transparent and robust systems that collect reviews from trusted sources. Only trustworthy reviews help consumers make the right decisions and give them the confidence to book.”
On March 8th , at 11:30 in the Travel Lab (hall 7.1c), Anson will outline best practises for ratings and reviews that help travel companies protect their reputations by preventing fake reviews. He’ll also explain how travel companies can use ratings and reviews to drive traffic to their websites, keep customers on their sites and increase direct bookings with personalised engagement.
[ends]
Notes to editors
- Representatives from the media wishing to confirm a briefing with Reevoo either before or during ITB Berlin should contact Tim Donnelly Smith at Both Barrels Communications, +44 7978 800275, timds@bbcomms.co.uk or Mireia Fontbernat, Reevoo, mireiafontbernat@reevoo.com .
- Reevoo will be exhibiting in the eTravel World hall at ITB Berlin: hall 7.1c, stand 103
- Reevoo’s Founder & CEO, Richard Anson, will be giving at talk on best practises for ratings and reviews on March 8th at 11.30 in the Travel Lab (hall 7.1c).
About Reevoo
Reevoo (http://b2b.reevoo.com ) is a world-leading social commerce company, providing user-generated reviews and social content that increases revenues by an average of 18%. More than 150 major brands, including Octopus Travel, Sony, Ford and Orange, rely on Reevoo. Its solutions increase their traffic, direct bookings, customer engagement and loyalty.
Reevoo is active in 18 countries. Its trusted independent brand and social commerce expertise provide its clients with much higher volumes of trustworthy reviews, recommendations and social content than other solutions – all from people who have been confirmed as real customers. Complete social media and SEO integration delivers more traffic directly to its customer’s websites, while advanced analytics tools make it easy to track and optimise performance.
Contact:
Both Barrels Communications Ltd
Tim Donnelly Smith
Tel.
+44-7978-800275
timds@bbcomms.co.uk
or
Reevoo
Mireia
Fontbernat
mireiafontbernat@reevoo.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 Data for Incyte’s Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet13.6.2025 00:45:00 CEST | Press release
POD1UM-303/InterAACT 2 is the first and largest global Phase 3 trial evaluating a PD-1 inhibitor in combination with chemotherapy for the treatment of patients with advanced SCAC not previously treated with systemic chemotherapy The trial met its primary endpoint; treatment with retifanlimab in combination with platinum-based chemotherapy (carboplatin-paclitaxel) resulted in clinically meaningful improvements in progression-free survival and overall survival In May 2025, the U.S. Food and Drug Administration (FDA) approved Zynyz® (retifanlimab-dlwr) in combination with carboplatin and paclitaxel and as a single agent for the treatment of advanced SCAC; submissions to other global regulatory agencies are also under review Incyte (Nasdaq:INCY) today announced that primary results from the Phase 3 POD1UM-303/InterAACT 2 trial of retifanlimab (Zynyz®), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), in combination with carboplatin and paclitaxel (platinum-base
Güntner Drives Group-Wide Innovation in 2024 Sustainability Report12.6.2025 21:30:00 CEST | Press release
Progress in natural refrigerants, water efficiency and circular economy underscores Güntner’s global impact Güntner, a global leader in refrigeration and heat exchange technology, today announced its featured role in the newly released 2024 A-HEAT Sustainability Report. The report outlines significant progress toward ambitious environmental goals—fueled by Güntner’s commitment to measurable, innovation-led sustainability. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612897493/en/ Güntner advances global sustainability goals with progress in natural refrigerants, water savings, and circular economy efforts. Working toward its 2030 sustainability targets, Güntner delivered significant achievements across key areas including natural refrigeration integration, water and energy efficiency and the development of circular economy solutions. These efforts reflect Güntner’s ongoing mission to make sustainability not just a goal,
Windsurf Launches First GPU Cluster in Germany, Expanding Secure Enterprise AI in Europe12.6.2025 20:45:00 CEST | Press release
Windsurf launches a GPU cluster in Germany, delivering 50% faster performance and secure access to European enterprises. Data residency ensures enterprise repositories stay within the EU, meeting stringent security requirements. Windsurf already supports 100+ European enterprise customers, highlighting strong demand for AI-powered development tools across EMEA. Windsurf, a leader in AI-powered software development, today announced its first GPU cluster in Germany, as product demand surges and the company expands performance capacity across the EU. With over 100 local enterprise customers already using Windsurf products, the new cluster marks the company’s first major international step in building scalable infrastructure for the European market. Located in Frankfurt, home to some of the world’s strictest data security laws, the cluster was a natural choice for Windsurf’s first deployment. This cluster was specifically designed to meet the unique security and performance requirements of
Xsolla Partners With Defold to Enable Seamless In-game Purchases for Web Developers12.6.2025 19:00:00 CEST | Press release
New SDK Integration Simplifies Monetization for Defold Developers Publishing on CrazyGames Ahead of Global Game Jam Xsolla, a leading global video game commerce company, announces a new strategic partnership with Defold, the cross-platform game engine trusted by professionals and indie developers worldwide. This collaboration introduces a seamless integration between Xsolla and Defold-built web games on CrazyGames, enabling developers to easily monetize their titles just in time for the CrazyGames x Defold Game Jam running June 13–15. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612569206/en/ (Graphic: Xsolla) To address the complexity of in-game monetization, Xsolla and Defold have developed a new SDK that allows Defold developers to implement in-game purchasing functionality without the complex manual API setup required. With Xsolla’s sponsorship and support, this integration removes friction from the monetization jou
Pioneering Cancer Plasticity Atlas will Help Predict Response to Cancer Therapies12.6.2025 17:00:00 CEST | Press release
The Wellcome Sanger Institute, Parse Biosciences, and the Computational Health Center at Helmholtz Munich today announced a collaboration to build the foundation of a single cell atlas, focused on understanding and elucidating cancer plasticity in response to therapies. The collaboration will catalyze an ambitious future phase to develop a cancer plasticity atlas encompassing hundreds of millions of cells. Utilizing novel organoid perturbation and Artificial Intelligence (AI) platforms, the aim is to create a comprehensive dataset to fuel foundational drug discovery models and cancer research. Dr. Mathew Garnett, Group Leader at the Sanger Institute, and Prof. Fabian Theis, Director of the Computational Health Center at Helmholtz Munich and Associate Faculty at the Sanger Institute, will be the principal investigators in the collaboration. Garnett’s research team has generated novel 3D organoid cultures that serve as highly scalable and functional cancer models with the ability to capt
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom